Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells. We found that the cell lines that express both HER2 and HER3 appear to have a higher phosphorylation level of Akt (activated Akt). Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Selective inhibition of PI-3K or Akt activity with their respective dominant-negative expression vectors sensitized the cells to the induction of apoptosis by the chemotherapeutic agents. We further demonstrated that MCF7 cells expressing a constitutively active Akt, in which the phospholipid-interactive PH domain of Akt was replaced by a farnesylation sequence for constitutive membrane anchorage (DPH-Akt1-farn), showed a similar increased resistance to the chemotherapeutic agents. Our results suggest that activation of Akt1 by HER2/PI-3K plays an important role in conferring a broad-spectrum chemoresistance on breast cancer cells and that Akt may therefore be a novel molecular target for therapies that would improve the outcome of patients with breast cancer.
Introduction
Breast cancer is second only to lung cancer as a cause of cancer-related deaths among women in the United States, with 203 500 estimated new cases in 2002 or almost 16% of all cancers in this country (Alessi and Cohen, 1998) . Surgery or radiation treatment is unfortunately not a choice for every patient. Patients with locally advanced or metastatic breast cancer may initially respond to chemotherapy or hormonal therapy, but the disease often progresses within a few months to a few years after therapy. One of the important factors contributing to the failure of chemotherapy in patients with breast cancer is that the cancer cells become resistant to drug-induced apoptosis. While it is generally acknowledged that the resistance of cancer cells to conventional chemotherapy is affected by multiple factors, the members of the human epidermal growth factor receptor (HER) family, which are overexpressed in approximately 30% of human breast cancer carcinomas, have been shown to play a major role in the chemoresistance of breast cancer cells (Yu and Hung, 2000) .
Akt, a serine-threonine protein kinase regulated by the intracellular levels of phospholipids, is one of the central players in oncogenesis (Testa and Bellacosa, 2001) . The first evidence pointing to a role of Akt in oncogenesis came from earlier studies in cloning a retrovirus isolated from the AKR mouse T-cell lymphoma (Bellacosa et al., 1991) . Overexpression of Akt2-transformed NIH3T3 cells (Cheng et al., 1997) and Akt2 antisense RNA inhibited Akt2-mediated tumorigenesis (Cheng et al., 1996) . Overexpression of Akt2 was found in 10-20% human ovarian and pancreatic cancers (Bellacosa et al., 1995; Cheng et al., 1996) , and increased kinase activity of Akt2 was found in approximately 30% of ovarian cancer specimens (Yuan et al., 2000) and 40% of breast cancer specimens (Sun et al., 2001) . In fact, an increase in Akt kinase activity without an accompanying increase in its expression level may have a broader effect on oncogenesis. In particular, an increase in Akt kinase activity could result from the activities of Akt upstream regulatory signals produced by overexpression or activation of the HER members, from the mutational activation of the Ras oncogene that activates Akt through the phosphoinoside-3 kinase (PI-3K) pathway (Datta et al., 1996; Liu et al., 1998) , or from the mutational inactivation of the PTEN phosphotase that normally inhibits Akt activity by dephosphorylating the PI-3,4,5 P 3 and PI-3,4 P 2 produced by PI-3K (Stambolic et al., 1998; Ramaswamy et al., 1999) .
Despite the demonstration that the overexpression or activation of HER members plays an important role in breast cancer oncogenesis (Slamon et al., 1987) , and that the activity of Akt was elevated in 40% of breast cancer patients (32 of 80 patient specimens) in a recent study (Sun et al., 2001) , there is a lack of direct demonstration showing that an aberration in HER2/PI-3K/Akt may lead to breast cancer cells resistance to chemotherapyinduced apoptosis. In this study, we used MCF7 cells as a target cell line and used two experimental approaches to delineate a pathway involving HER2/PI-3K/Akt in conferring on breast cancer cells resistance to a broadspectrum of chemotherapeutic agents. We demonstrated that the MCF7 cells engineered to express elevated levels of HER2 showed a PI-3K-dependent (LY294002-sensitive) increase in Akt activity. Compared with control vector-transfected cells, MCF7HER2 cells showed increased resistance to a panel of five chemotherapeutic agents with known different mechanisms of action. Selective inhibition of PI-3K or Akt in these HER2-overexpressing MCF7 cells with a dominantnegative expression vector of PI-3K or Akt reduced the levels of phosphorylated (activated) Akt and sensitized the cells to the chemotherapeutic agents. We further confirmed that expression of a constitutively active Akt vector alone in MCF7 cells caused similarly increased resistance of the cells to the chemotherapeutic agents. Our results therefore indicate that the HER2/PI-3K/Akt pathway plays a causal role in conferring a broad chemoresistance in breast cancer and justify a strategy for targeting this pathway for enhancing breast cancer chemotherapy.
Results
Expression of HER family proteins and activation status of Akt in human breast cancer cell lines Figure 1 shows the expression levels of the HER family members (HER1, HER2, and HER3) ( Figure 1a ) and the levels of total and phosphorylated Akt (Figure 1b ) in a panel of breast cancer cell lines. Akt was broadly expressed in all cell lines tested; however, the activated (phosphorylated) Akt appeared to be found mainly in the cell lines that express both HER2 and HER3 (MDA453, MDA361, MCF7). This is particularly evident when compared to the levels of phosphorylated Akt between MCF7 cells and MCF7 cells transfected with high level of HER2 (Figure 1b) . Cell lines that have high levels of only HER1 (MDA231), HER2 (BT474 and SKBR3), or HER3 (MDA435) did not show an increased level of phosphorylated Akt. MDA 468 cells are exceptional because PTEN is not functional in these cells (Teng et al., 1997) . These observations suggest that the potential heterodimerization and cross-talk between HER2 and HER3 may play an important role in mediating the downstream pathway leading to activation of Akt in breast cancer cells.
PI-3K-dependent phosphorylation of Akt and increased chemoresistance in MCF7 cells expressing high levels of HER2
We next focused on the activation of Akt and its potential role in mediating resistance to chemotherapy. We then examined the sensitivity of these MCF7HER2 cells to a panel of five chemotherapeutic . The dose required to achieve 50% of the numbers of untreated cells increased 2-4 log scales (paclitaxel: from 0.001 mm for MCF7neo cells to >0.1 mm in MCF7HER2 cells; doxorubicin: from 0.01 to >1 mm, 5-fluorouracil: from 50 to >1000 mm, etoposide: from 1 to >100 mm; and camptothecin: from 0.1 to >10 mm).
To determine whether the increased resistance of MCF7HER2 cells to the panel of breast cancer drugs involved the PI-3K/Akt pathway, we examined whether the selective inhibition of PI-3K or Akt activity would sensitize the MCF7HER2 cells to these chemotherapeutic agents. Expression of the dominant-negative counterpart of PI-3K or Akt sensitized the cells to the drug-induced apoptosis in all the five drugs tested (Figure 4 ). The results indicate that PI-3K and Akt are important in mediating the broad chemoresistance observed in MCF7HER2 cells.
Increased chemoresistance in MCF7 cells expressing high levels of constitutively active Akt (DPH-Akt1-farn)
To further determine the role of Akt in mediating the resistance of MCF7HER2 cells to the panel of chemotherapeutic agents, we constructed a Flag-tagged constitutively active (PI-3K-independent) Akt expression vector by replacing the phospholipid-interactive PH domain of Akt1 with a farnesylation sequence for directing constitutive membrane anchoring. This newly constructed vector, termed Flag-DPH-Akt1-farn, was transfected into MCF7 cells. Following several rounds of selection, over 10 clones transfected with either Flag-DPH-Akt1-farn vector or with pcDNA3.1 backbone (control) vector were obtained. Figure 5 shows the results of Western blot analysis of one control vectortransfected clone (pcDNA3.1-hyg) and three representative Flag-DPH-Akt1-farn vector-transfected clones (clones 7, 8, and 10) that express the highest levels of Flag-DPH-Akt1-farn (Figure 5a ). In contrast to endogenous Akt, which migrated as an approximately 56 kDa protein on an SDS-PAGE, the DPH-Akt1-farn appeared as a 50 kDa protein because of the deletion of its PH domain (from amino acids 1 to 106). Western blot analyses with antibodies directed against phosphorylated Akt1 showed that, compared with the results for control vector-transfected MCF7 cells, the farnesylated DPH-Akt1 but not endogenous Akt demonstrated markedly increased phosphorylation in the DPH-Akt1-farn-transfected MCF7 clones 7, 8, and 10 ( Figure 5a ). This was associated with increased phosphorylation of the Akt substrates, Bad and GSK3, in clones 7, 8, and 10 ( Figure 5b) . Since Bad or GSK3 could also be phosphorylated by kinases other than Akt1 in the cytoplasm, we further demonstrated that the farnesylated (Dp85) or Akt (M179A/T308/A/S473A). Cells were then exposed to the indicated concentrations of chemotherapeutic agents (5 mm paclitaxel, 20 mm doxorubicin, 5 mm 5-fluorouracil, 40 mm etoposide, or 1 mm camptothecin) for 8 h, followed by additional 16 h drug-free culture period. The percentage of drug-induced apoptosis was determined by Hoechst 33342 staining. Cells stained blue without condensed chromatin were recorded as nonapoptotic cells, whereas the cells stained blue with condensed chromatin were recorded as apoptotic cells Figure 5 Characterization of MCF7 cells expressing a constitutively active form of Akt. MCF7 cells transfected with control vector (MCF7hyg) or DPH-Akt1-farn (clones 7, 8, and 10) were cultured in 0.5% FBS medium for 48 h. The expression and phosphorylation levels of transfected Akt and two of its well-known substrates (Bad and GSK3) were examined by Western blot analyses with antibodies directed against Flag or ser473-phosphorylated Akt (a) or against phosphorylated Bad or phosphorylated GSK3 (b). In (c), the cell lysates described in (a) and (b) was used for Akt in vitro kinase assay using a GST-GSK3 peptide or a GST-Bad as substrates as described in Materials and methods. In (d), one representative clone (clone 10) was exposed to increasing concentrations of LY 294002 in 10% FBS culture medium for 24 h, followed by Western blot analysis with antibodies directed against ser473-phosphorylated Akt, total Akt, or b-actin; p ¼ phosphorylated HER2/PI-3K/Akt pathway in breast cancer chemoresistance C Knuefermann et al independent), we examined the Akt phosphorylation levels following exposure of the cells to the PI-3K inhibitor LY294002 for 24 h. In contrast to the serumstimulated phosphorylation of endogenous Akt, which was sensitive to the inhibition of PI-3K by LY294002 in a dose-dependent manner (Figure 5d , upper band), the phosphorylation level of the truncated Akt1 (DPHAkt1-farn) was not subject to regulation by LY294002, suggesting that the farnesylation-induced Akt1 phosphorylation was not mediated by PI-3K and thus is constitutively active. We then compared the sensitivity of the control vector-transfected MCF7 cells with that of the DPHAkt1-farn vector-transfected MCF7 cells (clones 7, 8, and 10) to the chemotherapeutic drugs doxorubicin, paclitaxel, 5-fluorouracil, etoposide, and camptothecin. Compared with the results for the control vectortransfected MCF7 cells, DPH-Akt1-farn vector-transfected clone 10 cells showed universally increased resistances to all five chemotherapeutic agents ( Figure 6 ). Similar results were also observed in the clones 7 and 8 cells (data not shown). These results strongly indicate that, once activated, Akt can confer on MCF7 cells resistance to conventional breast cancer chemotherapy.
Taken together, our data indicate that the HER2/PI-3K/Akt pathway plays an important role leading to multidrug resistance in MCF7 breast cancer cells and justify a strategy for targeting this pathway for sensitizing breast cancer cells to conventional chemotherapy.
Discussion
The PI-3K pathway, regulated by HER2-mediated tyrosine kinase activity, has been shown to play a critical role in promoting cell proliferation and inhibiting cell death. HER2-overexpressing cells often display an increased requirement for the PI-3K signaling pathway in anchorage-independent growth (Hermanto et al., 2001) . Akt, the cellular homologue of the viral oncogene v-akt, plays a major role in mediating such effects of PI-3K. Endocrine-treated breast cancer patients with activated Akt in their cancer have a worse outcome (Perez-Tenorio and Stal, 2002) . However, it has not been established whether increased activity of Akt could directly render breast cancer resistant to chemotherapy. In our study, we demonstrated in MCF7 cells that experimental elevation of HER2 protein showed increased phosphorylation of Akt and increased resistance to the five chemotherapeutic agents used, which included those that are currently used in patients with breast cancer. This is consonant with earlier studies demonstrating the amplification or overexpression of HER2 seen in 20-30% of breast cancer patients and its association with a poor clinical prognosis (Slamon et al., 1987 (Slamon et al., , 1989 . We confirmed that the HER2-mediated increase in chemoresistance was accompanied by increased Akt kinase activity, and the increases in both chemoresistance and in Akt activity are sensitive to the treatment of the cells with selective inhibition of PI-3K with a specific inhibitor or dominant-negative Figure 6 Increased resistance to chemotherapeutic agents of MCF7 clones expressing farnesylated Akt1. The control vectortransfected MCF7hyg cells (~) and the Flag-tagged DPH-Akt1-farn-transfected MCF7 clone 10 cells (') were pulse exposed to increasing concentrations of doxorubicin, paclitaxel, etoposide, camptothecin, or 5-fluorouracil for 3 h. The cells were then cultured for an additional 72 h in normal culture medium with 10% charcoal-stripped FBS. Relative cell numbers were determined with an MTT assay as described in Materials and methods HER2/PI-3K/Akt pathway in breast cancer chemoresistance C Knuefermann et al expression vector, indicating that the effects were mediated through PI-3K. Since activation of PI-3K may lead to multiactivation of other PI-3K downstream pathway substrates in addition to Akt, we further investigated the role of Akt in conferring chemoresistance on the same cells. We demonstrated that expression of a constitutively active Akt conferred on MCF7 cells resistance to a panel of five chemotherapeutic agents.
In this study, we tested a new form of constitutively active Akt. Under physiological conditions, the PH domain of Akt interacts with the phospholipid products of PI-3K, PtdIns (PI-3,4,5 P 3 and PI-3,4 P 2 ). The latter triggers the translocation of Akt to the cell membrane to be phosphorylated by PDKs. Instead of adding a myristoylation sequence to Akt, as has been previously reported in the literature for creating PtdIns-independent and irreversible membrane-anchoring potential (Alessi and Cohen, 1998), we created DPH-Akt1-farn, which should be cleavable by the farnesyl-esterases that are expressed in mammalian cells, thereby allowing its cytoplasmic relocalization. Our results indicated that the DPH-Akt1-farn was constitutively active as expected and was sufficient to mediate resistance to multiple chemotherapeutic agents in the MCF7 cells.
The involvement of Akt in human cancer oncogenesis and chemoresistance indicates that Akt is an important target for cancer therapy. In our study, MCF7 cells expressing constitutively active Akt or a high level of HER2 were uniformly resistant to a panel of five chemotherapeutic agents with different mechanisms of actions: paclitaxel (a microtubulin stabilizer), doxorubicin (an anthracycline), 5-fluorourocil (an antimetabolite), etoposide (a DNA-damaging agent), and camptothecin (a topoisomerase I inhibitor). These results suggest that Akt-mediated resistance to chemotherapy is likely because of an overall antiapoptotic activity of Akt and, further, that activation of the PI-3K signaling cascade leads to multidrug resistance. Akt is an important regulator of cell survival and apoptosis. Upon its activation, Akt can suppress apoptosis by interacting with and phosphorylating several key downstream effectors. For example, Akt phosphorylates the proapoptotic Bcl-2 partner Bad, which binds to and blocks the activity of Bcl-x, a cell survival factor (del Peso et al., 1997); inactivates the initiation caspase-9 (Cardone et al., 1998) ; represses the forkhead transcription factor FKHRL-1 (Brunet et al., 1999) , which regulates the expression of the apoptosis-inducing Fas ligand; and phosphorylates IkB, which promotes degradation of IkB and thereby increases the activity of NFkB, a wellknown cell survival factor (Ozes et al., 1999; Romashkova and Makarov, 1999) . In addition to these molecules that are known to be involved in apoptosis, there are increasing number of substrates that are also phosphorylated by Akt (see the recent review by Nicholson and Anderson, 2002) . Determination of which of these Akt downstream substrates are or are not involved in contributing to the chemoresistance on these MCF7 cells in our experimental model may further our understanding of the mechanism of the HER2/PI-3K/Akt pathway in mediating chemoresistance in breast cancer as well as many other types of human cancer cells.
Akt may be a better target than its upstream targets such as HER2, Ras, or PI-3K in sensitizing cancer cells to chemotherapy or radiotherapy, because it is located at an important convergent point that may be activated by multiple upstream signal transduction pathways. Direct targeting of Akt may avoid 'bypass' or alternating activation of Akt that may occur when the Akt upstream stimulatory pathways are only partially inhibited.
In summary, we demonstrated that Akt plays an important role in protecting human breast cancer cells against chemotherapy-mediated cytotoxicity. Our data therefore suggest that there could be clinical benefits from an appropriate combination of conventional chemotherapeutic drugs with a new generation of signal transduction inhibitors that inhibit the HER/PI-3K/Akt pathway for the treatment of breast cancer.
Materials and methods

Antibodies and reagents
Anti-Flag monoclonal antibody was obtained from Sigma Chemical Co. (St Louis, MO, USA) Antibodies directed against total Akt, ser473-phosphorylated Akt1, GSK3, phosphorylated GSK3, Bad, and phosphorylated Bad were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). Protein A-sepharose beads, which were used for immunoprecipitation experiments, were purchased from Repligen Corp. (Cambridge, MA, USA). The antineoplastic agents used in this study were paclitaxel (Taxol) and etoposide (VePesid) (Bristol Laboratories, Princeton, NJ, USA); doxorubicin (Adriamycin) (Gensia Sicor Pharmaceuticals, Irvine, CA, USA); 5-fluorouracil (Adrucil) (Pharmacia, Kalamazoo, MI, USA); and camptothecin (Sigma Chemical Co.). LY294002 was obtained from CalBiochem Corp. (San Diego, CA, USA). All other reagents were purchased from Sigma Chemical Co. unless otherwise specified.
Cells and cell culture
MCF7 human breast cancer cells were obtained from American Type Culture Collection (Manassas, VA, USA). The cells were grown and routinely maintained in Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% fetal bovine serum (FBS), 2 mm glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were incubated at 371C with 5% CO 2 and 95% air.
Construction of an expression vector encoding DPH-Akt1-farn
Total RNA was prepared from MCF10A human mammary epithelial cells using the RNeasy kit from Qiagen Inc. (Valencia, CA, USA) and subsequently was reversely transcribed into cDNA with the first-strand cDNA kit from Roche Diagnostics (Indianapolis, IN, USA) . DPH-Akt1-farn was constructed by two PCR procedures. The first PCR was performed using the cDNA as the template to amplify the DPH-Akt1 with the first pair of primers that contains a partial (18 bp) Flag sequence (5 0 -AAGGACGACGACGACCTG-3 0 ) and 22-bp DPH-Akt1 initial coding sequence in the forward HER2/PI-3K/Akt pathway in breast cancer chemoresistance C Knuefermann et al primer (5 0 -AAGGACGACGACGACCTGGAATTCGCT-GACGGCCTCAAGAA-3 0 ) and a partial (24 bp) farnesylation sequence (5 0 -CTTGCTCTTCTTCTTCTTCTTCTT-3 0 ), a XbaI restriction site, and 15-bp DPH-Akt1 ending coding sequence (before the stop code) in the reverse primer (5 0 -CTTGCTCTTCTTCTTCTTCTTCTTTCTAGAGGCCGT-GCTGCTGGC-3 0 ). In the second PCR, the product from the first PCR was extended by a second pair of primers containing the NheI restriction site, Kozak sequence, and the Flag sequence (24 bp) in the forward primer (5 0 -ATGCTAGCGC-CACCATGGACTACAAGGACGACGACGAC-3 0 ) and a PmeI restriction site, stop code, and the farnesylation sequence (42-bp) in the reverse primer (5 0 -TATGTTTAAACTCACAT-GATCACGCACTTGGTCTTGCTCTTCTTCTT-3 0 ). The final PCR product encoded Akt1 lacking its PH domain (amino acids 1-106) with an N-terminal fusion of the Flag epitope (DYKDDDDK) and a C-terminal fusion of a poly-basic tail and a farnesylation sequence (KKKKKKSKTKCVIM). The PCR fragment was subcloned into the pcDNA 3.1-hygro (Invitrogen, Carlsbad, CA, USA) via the restriction sites NheI and PmeI. The final Akt sequence was confirmed to be free of errors.
Establishment of MCF7 cell clones expressing DPH-Akt1-farn
Transfection was performed with the Fugene-6 transfection kit (Roche Diagnostic). MCF7 cells were transfected with the pcDNA3.1 backbone vector or the vector containing APHAkt1-farn, followed by selection with a medium containing 200 mg/ml hygromycin. Stable clones were evaluated for Flagtag expression by Western blot analysis with Flag-specific antibodies.
Western blot analysis
Cells were lysed in a lysis buffer containing 50 mm Tris, pH 7.4, 150 mm NaCl, 0.5% NP-40, 50 mm NaF, 1 mm Na 3 VO 4 , 1 mm phenylmethylsulfonyl fluoride, 25 mg/ml leupeptin, and 25 mg/ ml aprotinin. The lysates were cleared by centrifugation, and the supernatants were collected. Equal amounts of lysate protein were used for the Western blot analyses with the indicated antibodies (Fan et al., 1995) . Specific signals were visualized using the ECL chemoluminescence detection kit (Amersham, Arlington Heights, IL, USA).
Akt kinase assay
The Akt kinase assay was performed with a kit from Cell Signaling Technology, Inc with modifications. Briefly, Akt1 was immunoprecipitated from the cell lysate by an anti-Akt1 antibody, followed by an in vitro kinase reaction using GSTfused GSK3 or GST-fused Bad protein as a substrate in the presence of ATP. Phosphorylation of GSK3 or Bad was measured by Western blot analysis using antiphosphorylated GSK3 or antiphosphorylated Bad antibody.
Chemotherapy cytotoxicity assay
Cells were seeded onto 24-well culture plates. After the cells were exposed to various doses of chemotherapeutic agents and incubated for the indicated time intervals, cell viability was assessed by adding 50 ml of 10 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma) to 0.5 ml of culture medium and incubating the cells for 3 h at 371C in a CO 2 incubator, followed by cell lysis with 500 ml of lysis buffer containing 20% SDS in dimethyl formamide/H 2 O (1 : 1, v/v), pH 4.7, at 371C for more than 6 h. Cell viability was then determined by measuring the optical absorbance of cell lysates at a wavelength of 595 nm and normalizing the value with the value of the corresponding control (untreated cells).
Hoechst staining
Cells (5 Â 10 5 ) were washed once with serum-free DMEM and then resuspended in 1 ml of serum-free DMEM containing 1 mg/ml Hoechst 33342 (Molecular Probes, Inc., Eugene, OR, USA) and 50 mg/ml propidium iodide (Roche Diagnostics Corp., Indianapolis, IN, USA) for 15 min at 371C. The cells were washed with 1 ml of serum-free DMEM three times and then resuspended in 400 ml of DMEM. The cell suspension was dropped onto glass slides and immediately observed under a fluorescent microscope.
Abbreviations DPH-Akt1-farn, Flag-tagged farnesylation Akt1 lacking the PH domain; PI, phosphatidylinositol; PI(3,4,5) P3, PI 3,4,5-triphosphate; PI-3K, phosphoinoside-3 kinase; FBS, fetal bovine serum.
